Haemonetics (NYSE:HAE) Stock: Insider Farris Maryanne Maunsell Sells 836 Shares

Haemonetics Corporation (NYSE:HAE) CAO Farris Maryanne Maunsell sold 836 shares of Haemonetics stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $120.99, for a total transaction of $101,147.64. Following the completion of the transaction, the chief accounting officer directly owned 5,828 shares in the company, valued at approximately $705,129.72. The trade was a 12.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Haemonetics Stock Up 0.4%

Shares of Haemonetics stock traded up $0.45 on Friday, hitting $123.16. The company had a trading volume of 439,677 shares, compared to its average volume of 686,811. The firm has a market capitalization of $5.61 billion, a P/E ratio of 55.23, a P/E/G ratio of 2.45 and a beta of 0.63. Haemonetics Corporation has a twelve month low of $51.00 and a twelve month high of $132.00. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.84 and a quick ratio of 1.83. The stock has a 50-day moving average of $113.34 and a 200-day moving average of $81.36.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.06. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. The company had revenue of $357.76 million during the quarter, compared to the consensus estimate of $345.15 million. During the same quarter in the prior year, the firm earned $1.27 earnings per share. The firm’s revenue was up 9.4% compared to the same quarter last year. Research analysts predict that Haemonetics Corporation will post 5.32 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on HAE shares. Barrington Research lifted their price target on Haemonetics from $140.00 to $145.00 and gave the company an “outperform” rating in a research note on Friday, November 6th. Raymond James Financial upped their price objective on Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, September 3rd. BTIG Research upped their price objective on Haemonetics from $130.00 to $142.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a report on Wednesday, November 4th. Finally, Jefferies Financial Group initiated coverage on Haemonetics in a research report on Friday. They issued a “buy” rating and a $150.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.00.

Hedge Funds Weigh In On Haemonetics

A number of large investors have recently modified their holdings of HAE. Entropy Technologies LP acquired a new stake in shares of Haemonetics in the third quarter valued at about $2,134,000. Pathstone Holdings LLC bought a new stake in Haemonetics during the third quarter worth about $215,000. Marshall Wace LLP boosted its position in Haemonetics by 52.0% during the third quarter. Marshall Wace LLP now owns 46,344 shares of the medical instruments supplier’s stock valued at $4,880,000 after purchasing an additional 15,851 shares during the last quarter. Empowered Funds LLC acquired a new position in Haemonetics during the third quarter valued at approximately $1,624,000. Finally, First Trust Advisors LP boosted its position in Haemonetics by 8.3% during the third quarter. First Trust Advisors LP now owns 68,637 shares of the medical instruments supplier’s stock valued at $7,227,000 after purchasing an additional 5,279 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.